Apollo Health and Beauty Care Granted Research and Development License Under the Cannabis Act
Acasta Enterprises Inc. announced today that its wholly-owned subsidiary, Apollo Health and Beauty Care Inc. (“Apollo”) has been granted a research and development license (the “License”) by Health Canada pursuant to the Cannabis Act.
The License will permit Apollo to perform research and development of cosmetics containing CBD pursuant to its research protocol submitted to Health Canada. Research and development by Apollo will be conducted at its state of the art, GMP-certified manufacturing facility located in Toronto. Apollo has, in addition, initiated the process which, when granted, would authorize Apollo to distribute and sell products which will be developed as a result of the research performed.
“The growth in CBD infused topicals is forecasted to be exponential in the coming years”, says Co-CEO, Charles Wachsberg. “Apollo is committed to its marketplace leadership in quality, innovation, and premium product development. CBD topicals will compliment and be incremental to our existing and broad array of lifestyle products. Our entry into the CBD sector will allow Apollo to optimally and reliably serve the evolving interests and aspirations of our cherished global clients”.
